Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily due to a reduction in fat tissue Export

@article{citeulike:5877537, abstract = {Aim: The effect on body composition of liraglutide, a once-daily human GLP-1 analogue, as monotherapy or added to metformin was examined in patients with type 2 diabetes (T2D).Methods: These were randomized, double-blind, parallel-group trials of 26 (LEAD-2) and 52 weeks (LEAD-3). Patients with T2D, aged 18201380 years, BMI 2264 40 kg/m2 (LEAD 2), 226445 kg/m2 (LEAD-3), and HbA1c 7.0201311.0\% were included. Patients were randomized to liraglutide 1.8 mg/day, 1.2 mg/day or 0.6 mg/day, placebo or glimepiride 4 mg/day, all combined with metformin 1.520132 g/day in LEAD-2 and to liraglutide 1.8 mg/day, 1.2 mg/day or glimepiride 8 mg/day in LEAD-3. LEAD-2/3: total lean body tissue, fat tissue and fat percentage were measured. LEAD-2: adipose tissue area and hepatic steatosis were assessed.Results: LEAD-2: fat percentage with liraglutide 1.2 mg/metformin and 1.8 mg/metformin was significantly reduced vs. glimepiride/metformin (p \< 0.05) but not versus placebo. Visceral and subcutaneous adipose tissue areas were reduced from baseline in all liraglutide/metformin arms. Except with liraglutide 0.6 mg/metformin, reductions were significantly different versus changes seen with glimepiride (p \< 0.05) but not with placebo. Liver to spleen attenuation ratio increased with liraglutide 1.8 mg/metformin possibly indicating reduced hepatic steatosis. LEAD-3: reductions in fat mass and fat percentage with liraglutide monotherapy were significantly different vs. increases with glimepiride (p \< 0.01).Conclusion: Liraglutide (monotherapy or added to metformin) significantly reduced fat mass and fat percentage vs. glimepiride in patients with T2D.}, address = {Faculty of Health Science, rebro University, Sweden; Diabeteszentrum, Bad Lauterberg im Harz, Germany; NIHR Oxford Biomedical Research Centre, OCDEM, Biomedical Research Centre, Oxford, UK; resund Diabetes Team AB, Lund, Sweden; Endocrinology and Metabolism, Aarhus University, Denmark; Novo Nordisk, Bagsvaerd, Denmark; Monash University, Melbourne, Australia; Baylor College of Medicine, Houston, TX, USA}, author = {Jendle, J. and Nauck, M. A. and Matthews, D. R. and Frid, A. and Hermansen, K. and D\"{u}ring, M. and Zdravkovic, M. and Strauss, B. J. and Garber, A. J.}, citeulike-article-id = {5877537}, citeulike-linkout-0 = {http://dx.doi.org/10.1111/j.1463-1326.2009.01158.x}, citeulike-linkout-1 = {http://www3.interscience.wiley.com/cgi-bin/abstract/122604733/ABSTRACT}, comment = {ESTUDIO CON DETERMINACION DE GRASA VISCERAL CON DEXA O CT}, doi = {10.1111/j.1463-1326.2009.01158.x}, issn = {1463-1326}, journal = {Diabetes, Obesity and Metabolism}, keywords = {bmi, body-composition, diabetes, incretins, obesity, rct}, number = {999A}, posted-at = {2009-10-02 16:17:02}, priority = {2}, title = {Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily due to a reduction in fat tissue}, url = {http://dx.doi.org/10.1111/j.1463-1326.2009.01158.x}, volume = {9999}, year = {2009} }

TY - JOUR ID - citeulike:5877537 L3 - citeulike-article-id:5877537 N2 - Aim: The effect on body composition of liraglutide, a once-daily human GLP-1 analogue, as monotherapy or added to metformin was examined in patients with type 2 diabetes (T2D).Methods: These were randomized, double-blind, parallel-group trials of 26 (LEAD-2) and 52 weeks (LEAD-3). Patients with T2D, aged 18201380 years, BMI 2264 40 kg/m2 (LEAD 2), 226445 kg/m2 (LEAD-3), and HbA1c 7.0201311.0% were included. Patients were randomized to liraglutide 1.8 mg/day, 1.2 mg/day or 0.6 mg/day, placebo or glimepiride 4 mg/day, all combined with metformin 1.520132 g/day in LEAD-2 and to liraglutide 1.8 mg/day, 1.2 mg/day or glimepiride 8 mg/day in LEAD-3. LEAD-2/3: total lean body tissue, fat tissue and fat percentage were measured. LEAD-2: adipose tissue area and hepatic steatosis were assessed.Results: LEAD-2: fat percentage with liraglutide 1.2 mg/metformin and 1.8 mg/metformin was significantly reduced vs. glimepiride/metformin (p < 0.05) but not versus placebo. Visceral and subcutaneous adipose tissue areas were reduced from baseline in all liraglutide/metformin arms. Except with liraglutide 0.6 mg/metformin, reductions were significantly different versus changes seen with glimepiride (p < 0.05) but not with placebo. Liver to spleen attenuation ratio increased with liraglutide 1.8 mg/metformin possibly indicating reduced hepatic steatosis. LEAD-3: reductions in fat mass and fat percentage with liraglutide monotherapy were significantly different vs. increases with glimepiride (p < 0.01).Conclusion: Liraglutide (monotherapy or added to metformin) significantly reduced fat mass and fat percentage vs. glimepiride in patients with T2D. IS - 999A JF - Diabetes, Obesity and Metabolism SN - 1463-1326 AD - Faculty of Health Science, rebro University, Sweden; Diabeteszentrum, Bad Lauterberg im Harz, Germany; NIHR Oxford Biomedical Research Centre, OCDEM, Biomedical Research Centre, Oxford, UK; resund Diabetes Team AB, Lund, Sweden; Endocrinology and Metabolism, Aarhus University, Denmark; Novo Nordisk, Bagsvaerd, Denmark; Monash University, Melbourne, Australia; Baylor College of Medicine, Houston, TX, USA TI - Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily due to a reduction in fat tissue VL - 9999 KW - bmi KW - body-composition KW - diabetes KW - incretins KW - obesity KW - rct N1 - ESTUDIO CON DETERMINACION DE GRASA VISCERAL CON DEXA O CT AU - Jendle, J AU - Nauck, MA AU - Matthews, DR AU - Frid, A AU - Hermansen, K AU - Düring, M AU - Zdravkovic, M AU - Strauss, BJ AU - Garber, AJ PY - 2009/// UR - http://dx.doi.org/10.1111/j.1463-1326.2009.01158.x ER -